Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.29 USD | -0.83% |
|
+3.94% | -26.39% |
06-17 | Truist Securities Initiates Legend Biotech With Buy Rating, $88 Price Target | MT |
06-03 | Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.39% | 8.14B | |
+15.20% | 122B | |
+19.67% | 113B | |
+18.95% | 26.49B | |
-23.86% | 19.4B | |
-19.03% | 16.24B | |
-20.90% | 15.4B | |
-46.14% | 15.15B | |
+63.85% | 14.93B | |
+4.49% | 13.52B |
- Stock Market
- Equities
- LEGN Stock
- News Legend Biotech Corporation
- Transcript : Legend Biotech Corporation, Q4 2020 Earnings Call, Mar 18, 2021